Lorena Fontán
YOU?
Author Swipe
View article: JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models Open
Optimal T-cell activation arises from engagement of the T-cell receptor ('Signal 1') along with positive costimulatory signaling ('Signal 2'). CD28 is a positive costimulatory signaling molecule expressed constitutively by T-cells that bin…
View article: Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application Open
B cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-me…
View article: Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Activated B cell–like diffuse large B-cell lymphomas (ABC-DLBCL) have unfavorable outcomes and chronic activation of CARD11–BCL10–MALT1 (CBM) signal amplification complexes that form due to polymerization of BCL10 subunits, which is affect…
View article: Supplementary Figure from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Figure from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Figure from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Supplementary Figure from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Figure from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Figure from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Activated B cell–like diffuse large B-cell lymphomas (ABC-DLBCL) have unfavorable outcomes and chronic activation of CARD11–BCL10–MALT1 (CBM) signal amplification complexes that form due to polymerization of BCL10 subunits, which is affect…
View article: Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Supplementary Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Supplementary Data from BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
View article: Supplementary Figures and Methods from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Supplementary Figures and Methods from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Open
Figures S1 - S16 Supplementary Methods
View article: Supplementary Figures and Methods from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Supplementary Figures and Methods from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Open
Figures S1 - S16 Supplementary Methods
View article: Data from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Data from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Open
CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption o…
View article: Supplementary Tables from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Supplementary Tables from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Open
Tables S1 - S13
View article: Supplementary Tables from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Supplementary Tables from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Open
Tables S1 - S13
View article: Data from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Data from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Open
CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption o…
View article: Supplementary Figure Legends from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Figure Legends from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Supplementary Figure Legends S1-3
View article: Supplementary Tables from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Tables from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Supplementary Table S1. Patient characteristics. Supplementary Table S2. Characteristics of patients treated with ibrutinib. Supplementary Table S3. Primers and probes used for digital PCR. Supplementary Table S4. List of genes up- or down…
View article: Supplementary Figure Legends from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Figure Legends from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Supplementary Figure Legends S1-3
View article: Data from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Data from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B-cell receptor si…
View article: Supplementary Figures from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Figures from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Supp. Fig. S1: MI-2 causes a dose- and time-dependent apoptotic induction selectively in primary CLL cells with minimal toxicity to normal B cells. Supp. Fig. S2: Sensitivity to MI-2 is independent of clinical or biological features classi…
View article: Supplementary Figures from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Figures from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Supp. Fig. S1: MI-2 causes a dose- and time-dependent apoptotic induction selectively in primary CLL cells with minimal toxicity to normal B cells. Supp. Fig. S2: Sensitivity to MI-2 is independent of clinical or biological features classi…
View article: Supplementary Table Descritptions from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Table Descritptions from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Description and Legends for Supplementary Tables S1-5
View article: Supplementary Table Descritptions from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Table Descritptions from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Description and Legends for Supplementary Tables S1-5
View article: Data from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Data from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B-cell receptor si…
View article: Supplementary Tables from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Supplementary Tables from MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Open
Supplementary Table S1. Patient characteristics. Supplementary Table S2. Characteristics of patients treated with ibrutinib. Supplementary Table S3. Primers and probes used for digital PCR. Supplementary Table S4. List of genes up- or down…
View article: <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL Open
Activated B cell–like diffuse large B-cell lymphomas (ABC-DLBCL) have unfavorable outcomes and chronic activation of CARD11–BCL10–MALT1 (CBM) signal amplification complexes that form due to polymerization of BCL10 subunits, which is affect…